<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is a common <z:e sem="disease" ids="C0410787" disease_type="Disease or Syndrome" abbrv="">inherited disorder of connective tissue</z:e> caused by deficiency of the matrix protein fibrillin-1 </plain></SENT>
<SENT sid="1" pm="."><plain>Effective surgical therapy for the most life-threatening manifestation, aortic root <z:hpo ids='HP_0002617'>aneurysm</z:hpo>, has led to a nearly <z:mpath ids='MPATH_458'>normal</z:mpath> lifespan for affected individuals who are appropriately recognized and treated </plain></SENT>
<SENT sid="2" pm="."><plain>Traditional medical therapies, such as beta-adrenergic receptor blockade, are used to slow pathologic aortic growth and decrease the risk of <z:hpo ids='HP_0002647'>aortic dissection</z:hpo> by decreasing hemodynamic stress </plain></SENT>
<SENT sid="3" pm="."><plain>New insights regarding the pathogenesis of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> have developed from investigation of murine models of this disorder </plain></SENT>
<SENT sid="4" pm="."><plain>Fibrillin-1 deficiency is associated with excess signaling by transforming growth factor beta (TGFbeta) </plain></SENT>
<SENT sid="5" pm="."><plain>TGFbeta <z:chebi fb="68" ids="48706">antagonists</z:chebi> have shown great success in improving or preventing several manifestations of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> in these mice, including <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>These results highlight the potential for development of targeted therapies based on discovery of disease genes and interrogation of pathogenesis in murine models </plain></SENT>
</text></document>